Discover Great Companies Discover Great Clients
Popularity  17.7万   |   Followers  12   |   Likes  66   |   Feedback  12 Claim this company

Striving unremittingly for the cause of human health

No.237 Guangzhou City Popularity Ranking No.55 Huangpu District Guangdong No.1 Biotechnology Chemical No.1 Dong Gan Powders No.1 Vaccines Technology No.2 Vaccines No.2 Ren Yong Yi Miao No.2 Organic Raw Materials No.3 Zhu She Liquids No.3 Yuan Yan Yao No.3 Chong Agents No.3 Pharmaceutical APIs No.4 Pharmaceutical R&D No.4 Innovative Drugs Products 企业技术中心 国家高新技术企业 副会长单位 高新技术企业 市著名商标 GMP认证
More

Company Overview

  • Nature: Listed Company Size: 1000-4999 employees Founded: 24年
  • Industry: Pharmaceuticals/Bioengineering
  • Full name: ApicHope Pharmaceutical Group Co., Ltd.。

Development Stage

  • Stage: IPO上市, 。
  • Ranking: Ranked #237 in Guangzhou City by popularity Ranked #1 in Guangzhou Biotechnology Chemical Company by popularity Ranked #1 in Guangzhou Dong Gan Powders Company by popularity Ranked #1 in Guangzhou Vaccines Technology Company by popularity Ranked #2 in Guangzhou Vaccines Company by popularity
  • Honors: 2022中国中成药企业100强 2025中国化药研发实力100强 企业技术中心 国家高新技术企业 According to algorithm
  • News: 2026-09-20:一品红:复方聚乙二醇(3350)电解质口服溶液获注册证书。
  • Salary: 58.8% of positions earn 10-20K, In 2026 vs last yeardecreased by 5%.。Master's salary: ¥28.8K, Doctorate salary: ¥50.0K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 9%, "Computer/Network/Technology": 6.2%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 2.3%。
  • Recruiting: In 2026 vs 2025grew by 39%. Demand for highly educated talent: Master's: 39, Doctorate: 1.
  • Requirement: Education: 大专 leads with 63.9%. Experience: 1-3年 leads with 29.3%.
  • Region: Distributed across 64 regions, 广州: 24.1%, 上海: 4.2%, 成都: 2.5%, 北京: 2.2%.

About the Company

[Summary] Striving unremittingly for the cause of human health

ApicHope Pharmaceutical Co., Ltd. (ApicHope, 300723.SZ) was founded in 2002 and listed on the Shenzhen Stock Exchange in 2017. With approximately 1,700 employees, it is an innovative biopharmaceutical enterprise focusing on pediatric and chronic disease drugs. The company has built an office headquarters of over 50,000 square meters, an innovation and R&D center of over 60,000 square meters, and a digital production base of 220,000 square meters meeting EU and FDA standards. A 110-mu (approx. 7.3 hectares) API production base is scheduled to commence operations in 2024, completing the full industrial chain layout for pharmaceuticals. The company has assembled an innovative R&D team of over 400 members led by globally senior chief scientists. From 2021 to 2023, R&D investment totaled approximately RMB 1.3 billion, accounting for about 10% of annual revenue. It currently holds 187 drug registration approvals, with more than 10 new approvals added each year for three consecutive years. The company's technology platforms are synchronized globally: (1) High-end pediatric drug formulation technology platform: Currently holds 25 pediatric drug registration approvals and has 31 pediatric drug projects under development, aiming to become a leading enterprise with strong R&D capabilities and large scale in the pediatric drug field. (2) Chronic disease drug innovation R&D platform: Currently holds 63 chronic disease drug registration approvals and has 36 chronic disease drug projects under development. AR882, a global innovative gout drug in development, is a potent and highly selective uricosuric agent that has entered global multicenter Phase III clinical trials, with dosing completed in nearly one hundred patients. Completed global multicenter Phase IIb clinical trial data show that compared with existing therapies, AR882 demonstrates greater efficacy and higher safety in treating gout patients; in addition to lowering serum uric acid (sUA), it significantly reduces tophi, alleviates uric acid crystal burden, and lowers the incidence of acute gout flares. In August 2024, AR882 received Fast Track Designation (FTD) from the U.S. FDA. Breakthrough treatment results in dissolving tophi were presented as a keynote speech at the 2023 American College of Rheumatology (ACR) Annual Meeting and featured at the 2024 European Congress of Rheumatology (EULAR). Adhering to the corporate vision of "ApicHope for every family, bringing blessings to millions of households," the company, together with the China Soong Ching Ling Foundation, established the "China Soong Ching Ling Foundation ApicHope Children's Health Care Special Fund" to support pediatric disease research and improve the health service system for adolescents and children. It also engages in public welfare activities such as flood relief, poverty alleviation, educational assistance, and primary healthcare in rural areas, fulfilling corporate social responsibility. ApicHope persists in innovation and upholds quality, striving to provide patients with more and better drugs of superior quality and efficacy, benefiting the public, giving back to society, and making unremitting efforts for human life and health.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

ApicHope Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market:
  • Deal:

ApicHope How Fast Is Hiring Growing? (493 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 85%
  • 2024: Up 17%
  • 2023: Down 6%
  • 2022: Down 13%
ApicHope Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
ApicHope Campus Recruitment & Advanced Degree Talent Demand
Graduates 4 Interns 4 Master's 39 Doctorate 1
No.195
Company Recruitment Ranking in Guangzhou City 򀀩
No.1814
Recruitment Growth Ranking in Guangzhou City 򀀩
No.179
Graduate Talent Ranking in Guangzhou City 򀀩
No.278
Intern Talent Ranking in Guangzhou City 򀀩
Note: How fast is hiring at ApicHope Pharmaceutical Group Co., Ltd. growing? ApicHope2026: 931 openings (up 39%), 2025: 670 openings (up 85%), 2024: 363 openings (up 17%), 2023: 309 openings (down 6%), 2022: 328 openings (down 13%), 2021: 379 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

ApicHope Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Down 20%
  • 2024: Down 57%
  • 2023: Down 2%
  • 2022: Up 100%
ApicHope Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at ApicHope Pharmaceutical Group Co., Ltd. growing? ApicHopeMaster's recruitment over the years: 2025: 16 openings (down 20%), 2024: 20 openings (down 57%), 2023: 47 openings (down 2%), 2022: 48 openings (up 100%), 2021: 24 openings. ApicHope master talent ranking in Guangzhou: #69, ApicHope master salary mostly around 15-50K.

ApicHope Doctoral Degree Job Demand Analysis

(More)
Flat
Growth Rate
2026 vs 2025
  • 2025: Up 100%
  • 2024: Down 67%
  • 2023: Down 50%
  • 2022: Flat 0%-
ApicHope Doctoral Hiring by Year: 2026 — same as 2025
* Hiring was generally low during 2020-2022 due to the pandemic
No.425
Doctoral Demand Ranking in Guangzhou City 򀀩
¥50K and above-50K and above
Doctoral Salary 򀀩
How fast is doctoral hiring at ApicHope Pharmaceutical Group Co., Ltd. growing? ApicHopeDoctorate recruitment over the years: 2026: 2 openings (flat), 2025: 2 openings (up 100%), 2024: 1 openings (down 67%), 2023: 3 openings (down 50%), 2022: 6 openings (flat), 2021: 6 openings. ApicHope doctorate talent ranking in Guangzhou: #425, ApicHope doctorate salary mostly around 50K and above-50K and above.

ApicHope R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at ApicHope Pharmaceutical Group Co., Ltd.? Based on an analysis of ApicHope's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 9%, "Computer/Network/Technology": 6.2%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 2.3%, "Other (R&D and Technical)": 0.4%, "Mechanical/Instrumentation": 0.4%, "Electrical/Energy/Power": 0.4%. For reference only.

ApicHope — What Are the Salaries Like? (1120 records)

Manage
salary range: 4.5K - 50K, 58.8% of roles pay ¥10-20K
Note: salary statistics are based on 1120 salary records from the past year and depend on the job sample. For reference only.
How is the salary at ApicHope Pharmaceutical Group Co., Ltd.?ApicHope58.8% of positions earn 10-20K, Fresh graduate salary: ¥9.1K。Guangzhou salary ranking top 25,销售类 average salary ¥18.9K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of ApicHope

(More)
Are salaries high at ApicHope Pharmaceutical Group Co., Ltd.? We provide: Information, Regional Manager, 招商, Key Account Manager, 省区经理, 推广, Account Manager, dm, Retail, Trainer, Marketing, 区域经理, Product Manager, Business Manager, Regional Manager, Medical Science Liaison, Product Manager, QA, 儿科, HR Specialist. Click to view detailed salary analysis by job.

ApicHope — Fortune 500? (More)

Yes, ranked in 中国中成药企业100强:

  • NO.43 2022中国中成药企业100强 >

Yes, ranked in 中国化药研发实力100强:

  • NO.40 2025中国化药研发实力100强 >
  • NO.76 2024中国化药研发实力100强 >

ApicHope honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • 销售类
    66% of total 66%
  • 经营管理类
    25.2% of total 25.2%
  • 市场/公关/媒介类
    10.3% of total 10.3%
  • 医疗卫生/美容保健类
    9% of total 9%

Education

  • 大专
    63.9% of total 63.9%
  • 本科
    26.7% of total 26.7%
  • 硕士
    5.9% of total 5.9%
  • 高中
    2.9% of total 2.9%

Experience

  • 1-3年
    29.3% of total 29.3%
  • 5-10年
    28% of total 28%
  • 3-5年
    21.4% of total 21.4%
  • 不限
    20.2% of total 20.2%
View Detailed Analysis

What does ApicHope Pharmaceutical Group Co., Ltd. require? Who is ApicHope hiring? ApicHope recruitment: 销售类占比最多占66%,其次是经营管理类占25.2%. What education can get in at ApicHope? 大专占比最多占63.9%,其次是本科占26.7%. High education required at ApicHope? 硕士占5.9%,博士占0.2%. Work experience required at ApicHope? 1-3年占比最多占29.3%,其次是5-10年占28%. Where are the job locations at ApicHope? 广州占比最多占24.1%,其次是上海占4.2%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 45,169.2766万(元)
Legal Representative: 李捍雄
Date Established:
Credit Code: 914400007361542488
Registered Address: 广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层

Partners & Suppliers

合作开展干细胞与再生医学领域的研发 Source
供应商 科研机构
产学研合作协议,合作开发创新型药物制剂 Source
供应商 高校联合实验室
合作开发多价疫苗,引进华南疫苗的技术平台 Source
供应商 疫苗研发技术授权
签署战略合作框架协议,委托进行创新药研发服务 Source
供应商 CRO(合同研究组织)
签署战略合作协议,共建儿童药健康服务体系,开展线上营销与患者教育 Source
合作客户 医药电商平台

People who follow ApicHope also follow

ApicHope Competitors (Similar Companies)

“Professional design and supporting services for computer and communica”
呼叫中心 ISP 系统集成 企业服务
商业物业 政府物业 住宅物业 环卫
电镀设备 化学品 电镀 重型机械
传感器 模具制造/生产/加工 后视镜 摩托车配件
“Bringing benefits to patients”
“Smart city construction and operation provider”
“Innovation for Life”
“Design and sales of core chips for IoT intelligent hardware”
“Build a first-class platform to realize dreams.”
跨境电商/外贸 贸易 汽车产业链 海外
IT运维服务 IT外包 企业服务 服务外包
“Manufacturing of industrial automation equipment”
“Striving unremittingly for the cause of human health”
会展中心 办公空间 社区管理 建筑科技/技术

Discover Great Companies, Discover Great Clients

广州公司名录 广州“Huangpu District”公司名录 广州“医药”公司名录 广州“药物研发”公司名录 广州“原料药”公司名录 广州“化学制药”公司名录 广州“冻干粉”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates